Trillium Therapeutics Inc.
TRIL
TRIL was delisted on the 16th of November, 2021.
2 hedge funds and large institutions have $18K invested in Trillium Therapeutics Inc. in 2021 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 177 closing their positions.
99% less funds holding
Funds holding: 181 → 2 (-179)
99% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 177
100% less funds holding in top 10
Funds holding in top 10: 5 → 0 (-5)
100% less capital invested
Capital invested by funds: $1.38B → $18K (-$1.38B)
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$107M |
| 2 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$101M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
-$100M |
| 4 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$91.8M |
| 5 |
MF
Magnetar Financial
Evanston,
Illinois
|
-$57.4M |
TRIL Hedge Fund Activity: Q4 2021 in Review
2 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Trillium Therapeutics Inc. (TRIL) for Q4 2021, worth a combined $18K — down 100% from $1.38B a quarter earlier.
Sellers outnumbered buyers: 177 funds closed out of TRIL and 1 opened new positions — a net loss of 176 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was BlackRock, exiting entirely with an estimated $107M sold.
- 2 institutional investors held Trillium Therapeutics Inc. (TRIL) as of Q4 2021, down from 181 in Q3 2021.
- Funds reported $18K of Trillium Therapeutics Inc. stock for Q4 2021, down 100% quarter-over-quarter.
- 1 fund opened new Trillium Therapeutics Inc. positions in Q4 2021 and 177 closed out, a net change of -176 holders.
- The largest Trillium Therapeutics Inc. seller in Q4 2021 was BlackRock, an estimated $107M sold.
Based on aggregated 13F filings for Q4 2021.